Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche chairman Franz Humer framed the EUR 2.25B sale as a focus move on Roche's 'two high-tech pillars, pharmaceuticals and diagnostics'; Roche kept all…
EU Commission opened in-depth Phase II probe into the DSM/Roche Vitamins deal citing horizontal overlap concerns, particularly in feed enzymes.
FTC alleged the deal would violate Section 7 of the Clayton Act in feed phytase markets; DSM agreed to divest the phytase business to BASF as the consent…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
DSM acquired Roche's Vitamins & Fine Chemicals division for EUR 2.25B (approximately $2.24B) as part of Roche's refocus on its pharmaceuticals and diagnostics pillars following its vitamin price-fixing settlements. The transaction cleared on conditions, with the FTC requiring divestiture of the feed-phytase business to BASF and the EU Commission granting clearance in July 2003. DSM completed the acquisition with effect from September 30, 2003 and renamed the business DSM Nutritional Products.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| DSM N.V. / Roche Vitamins and Fine Chemicals Division (this deal) | 2002 | $2.2B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2002 deals